Corporate Profile for Gryphon Sciences, dated May 31, 1996.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services See Information Systems. . These include Dow Jones Dow Jones the best known of several U.S. indexes of movements in price on Wall Street. [Am. Hist.: Payton, 202] See : Finance News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine See AOL. , CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International UMI United States Minor Outlying Islands (ISO Country code) UMI University of Miami UMI Universal Management Infrastructure (IBM) Data Courier, NewsBank, Information Access Company, Prodigy, Comtex, and many others. -0- Published date: May 31, 1996 Company name: Gryphon Sciences
Address: 250 E. Grand Ave., Suite 90
South San Francisco, CA 94080
Telephone No.: 415/952-7714 Chief Executive Officer: Janice M. LeCocq Investor Relations Contact: Janice M. LeCocq Business number: 415/952-7714 Public Relations Contact: Janice M. LeCocq Business number: 415/952-7714 URL/email Address: conley@gryphonsci.com Company description: Gryphon Sciences' primary mission is to use advanced, proprietary technology for the total chemical synthesis In chemistry, chemical synthesis is purposeful execution of chemical reactions in order to get a product, or several products. This happens by physical and chemical manipulations usually involving one or more reactions. of proteins and protein-like molecules in the discovery and development of novel pharmaceuticals. Gryphon is focusing in three areas: 1) the creation of a new class of pharmaceuticals based on the use of mirror image proteins (Dextroceutical(TM) technology); 2) the chemical synthesis of large, complex multifunctional molecules for next generation vaccines and gene therapy (Nanoceutical(TM) products); and 3) chemical synthesis of new proteins and protein analogues for enhancing productivity of new molecule discovery programs. Gryphon can synthesize large and complex protein and protein-like molecules with a speed, efficiency and purity not available through conventional peptide synthesis In organic chemistry, peptide synthesis is the creation of peptides, which are organic compounds in which multiple amino acids bind via peptide bonds which are also known as amide bonds. technology. Furthermore, the chemistries are not limited to "biological" components, enabling Gryphon to synthesize structures that are impossible to obtain through bioengineering bioengineering Application of engineering principles and equipment to biology and medicine. It includes the development and fabrication of life-support systems for underwater and space exploration, devices for medical treatment (see . Gryphon plans to rely heavily on corporate collaborations, both as a source of resources for development and commercialization of potential products and for working capital. Gryphon expects to realize the value of its contribution through a combination of technology access payments, research funding Research funding is a term generally covering any funding for scientific research, in the areas of both "hard" science and technology and social science. The term often connotes funding obtained through a competitive process, in which potential research projects are evaluated and , milestone payments, royalties and manufacturing revenues. Gryphon received seed financing in February 1994 from S.R. One Limited, Falcon Technology Partners and Forward Ventures. CONTACT: Gryphon Sciences |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion